当前位置：
X-MOL 学术
›
Nat. Rev. Drug. Disc.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Immuno-oncology upset in bladder cancer
Nature Reviews Drug Discovery ( IF 120.1 ) Pub Date : 2017-05-31 , DOI: 10.1038/nrd.2017.108 Asher Mullard
Nature Reviews Drug Discovery ( IF 120.1 ) Pub Date : 2017-05-31 , DOI: 10.1038/nrd.2017.108 Asher Mullard
Roche and Genentech's checkpoint inhibitor atezolizumab did not improve overall survival in a confirmatory phase III trial in patients with advanced bladder cancer. The FDA granted accelerated approval to the anti-programmed cell death protein 1 ligand 1 (PDL1) antibody for this indication in 2016
中文翻译：
膀胱癌的免疫肿瘤学问题
Roche和Genentech的检查点抑制剂atezolizumab在一项证实性的III期晚期膀胱癌患者中并未改善总体生存率。FDA于2016年为该适应症授予了抗编程性细胞死亡蛋白1配体1（PDL1）抗体的加速批准
更新日期：2017-05-31
中文翻译：
膀胱癌的免疫肿瘤学问题
Roche和Genentech的检查点抑制剂atezolizumab在一项证实性的III期晚期膀胱癌患者中并未改善总体生存率。FDA于2016年为该适应症授予了抗编程性细胞死亡蛋白1配体1（PDL1）抗体的加速批准
京公网安备 11010802027423号